ALSO NOTED: FDA lifts ban on Watson plant in FL; Sanofi bolstered profits but lost in drug trial;

> Watson Pharmaceuticals finally saw the FDA lift its ban on new products from a Florida manufacturing plant, allowing drugs made there to be eligible for agency approval; the facility had been under a new-product hold since 2005. Report

> Sanofi-Aventis kept sales and profits higher than analysts expected--$10.81 billion and $3.92 billion respectively--but said its experimental antidepressant saredutant failed a clinical trial. Report

> Novo Nordisk beat market estimates with a 22 percent hike in first-quarter profits to $589 million on $2.21 billion in sales. Report

> Takeda Pharmaceutical and Millennium Pharmaceuticals announced that the FTC granted an early end to the waiting period for their merger. Report

> Federal legislation calling for nationwide pharma-tracking would pre-empt the statewide pedigree systems under development in California and Florida. Report

> Canada's Nova Scotia province will cover Avastin treatment for colorectal cancer patients after a long delay over questions about the med's cost-effectiveness. Report

> AstraZeneca asked the FDA to expand the use of its Symbicort asthma drug to cover chronic obstructive pulmonary disease, or COPD. Report

> The FDA has approved Amitiza for women 18 years old and older with IBS-C. The drug is co-marketed in the U.S. by Sucampo Pharmaceuticals and Takeda Pharmaceutical Co. Report

> Compliance with schizophrenia treatment is higher when patients have lower copays and unrestricted access to their meds, according to a new study. Report

> Medco Health Solutions saw its first-quarter profits drop by 1.7 percent to $270 million on higher costs as volume continued to grow. Report

> Pfizer is providing $14.4 million to fund a research consortium involving four universities and Entelos, a company that does computer modeling for drug research work, in a drive to create a new class of diabetes drugs. Report

> Management consultant Dr. David A. Shaywitz has joined with Dr. Dennis A. Ausiello, the physician-in-chief of Massachusetts General Hospital and a director at Pfizer, to deliver a rebuttal to a small group of research scientists who have sworn off any industry-financed drug research work. Report

> An international consortium of researchers has launched a billion-dollar effort to map every way that changes in DNA contributes to the development of tumors. Report

> Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Now Levin has sealed his reputation for raising cash with a $32 million Series A to get Constellation Pharmaceuticals up and running. Report

> With three significant development programs at work on a tamper-free alternative to the blockbuster OxyContin franchise, Purdue Pharma is bracing for an upcoming FDA panel review of its new pain therapy formulation. Report

> Unigene is racing to complete construction of new facilities in China that will house its joint venture with a Chinese pharma company. Report

And Finally ... Two new human trials of a gene therapy for inherited blindness have demonstrated that injecting replacement genes under the retinas of the blind can spur at least partial sight in some volunteers. Report

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.